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Case presentation
Patient 1. A 24-year-old woman with chronic renal failure secondary
to membranoproliferative glomerulonephritis underwent living-related
renal transplantation from her 56-year-old mother. Other than her renal
disease, she had no significant medical problems. She received cyclo-
sporine, prednisone, and azathioprine as immunosuppressive therapy
post transplant. The allograft functioned immediately, and the serum
creatinine concentration fell to I . I mg/dl 3 days after transplantation.
Because the donor was seropositive for cytomegalovirus (CMV), the
patient received CMV hyperimmune globin, 150 mg/kg intravenously
every 2 weeks, beginning on the first post-transplant day and continuing
until she presented with CMV infection on the 38th post-transplant day.
On the 10th day post transplant, the patient's temperature rose to 100.6°
F and she felt sick. Physical examination revealed no site of infection,
a chest radiograph was normal, and all cultures were negative; the
serum creatinine, however, had risen to 1.6 mg/dl. Ultrasound exami-
nation of the allograft revealed no fluid collection or evidence of
hydronephrosis. A clinical diagnosis of allograft rejection was made,
and 500 mg of methylprednisolone was administered intravenously on 2
consecutive days. Although the patient became afebrile, she became
increasingly oliguric, and her serum creatinine continued to rise (to 3.2
mg/dl). A percutaneous renal biopsy revealed acute allograft rejection
without evidence of cyclosporine toxicity; anti-rejection therapy with
OKT3 was initiated at a dose of 5 mg/kg for a total of 14 days. By the
end of this course of OKT3, the serum creatinine had returned to
normal. The therapeutic program then consisted of cyclosporine, 450
mg/day; prednisone, 20 mg/day; azathioprine, 100 mg/day; one single-
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strength tablet of trimethoprim-sulfamethoxazole (80 mg TMP, 400 mg
SMX); and clotrimazole, 10 mg twice daily.
The patient remained well until the 38th post-transplant day, when
she presented with fever to 102.4° F, increasing shortness of breath, a
nonproductive cough, and generalized malaise of 3 days duration.
Physical examination revealed an anxious woman who was slightly
dyspneic at rest; her temperature was 100.6° F; respiratory rate was 32
breaths/mm; and blood pressure was 140/95 mm Hg. The skin was
normal and her chest was clear; cardiac, abdominal, pelvic, and rectal
examinations were within normal limits, although her stool was positive
for occult blood. Laboratory evaluation revealed: hematocrit, 31%;
white blood cell count, 3100/mm3, with 47% polymorphonuclear cells,
15% monocytes, 28% lymphocytes, 6% atypical lymphocytes, and 4%
"bands"; and negative urinalysis and urine Gram stain. The serum
creatinine was 1.5 mg/dl; BUN, 46 mg/dl; and the SOOT, alkaline
phosphatase, bilirubin, and electrolytes all were within normal limits. A
chest radiograph revealed bilateral interstitial infiltrates, primarily
affecting the lower lobes. Arterial blood gases obtained while the
patient was breathing room air were: p0, 64mm Hg; pCO2, 31 mm Hg;
and pH, 7.46. Bronchoscopy with bronchoalveolar lavage was carried
out on the day of admission; no abnormalities were seen and monoclo-
nal antibody stains for Pneumocystis carinii were negative. However,
cytomegalovirus was isolated by culture of the bronchoalveolar lavage
fluid; CMV also was isolated from blood and urine. The bronchoalve-
olar lavage and urine cultures were positive for CMV 48 hours post
inoculation, whereas the blood culture was not positive for 3 weeks.
The patient was treated with ganciclovir, 5 mg/kg twice daily for 3
weeks, and hyperimmune anti-CMV immunoglobulin was reinstituted
at a dose of 150 mg/kg/week for 4 weeks. She was cared for in a
HEPA-filtered room for the first 10 days, and she was treated at home
with intravenous therapy thereafter. She made an excellent response
and remains well more than one year later.
Patient 2. A 6-year-old girl underwent cadaveric renal transplantation
because of end-stage renal disease secondary to obstructive uropathy.
Both donor and recipient were seronegative for cytomegalovirus, and
the recipient was seronegative for Epstein-Barr virus and varicella-
zoster virus as well. Post transplant, the patient was oliguric, and the
original immunosuppressive program of cyclosporine, prednisone, and
azathioprine was altered on the third post-transplant day; cyclosporine
was discontinued and OKT3 was initiated at a dose of 2.5 mg/kg/day.
Over a 10-day period, her renal function gradually improved; cyclospo-
rifle was restarted at the end of the 10-day course of OKT3. She was
discharged home with a serum creatinine of 0.6 mgldl. Over the next 3
months she had several minor bouts of allograft rejection, requiring a
total of 4 pulse doses of intravenous methylprednisolone, as well as an
increase in her daily dose of prednisone. She remained clinically well,
however, until 4 months post transplant, when she presented with 3
days of fever, increasing sore throat, anorexia, and malaise. Physical
examination was remarkable for enlarged, somewhat necrotic tonsils,
and an inflamed pharynx. No adenopathy was present, and other than
her somewhat cushingoid appearance, the rest of the physical exami-
nation was negative.
Laboratory evaluation revealed: hematocrit, 29%; white blood cell
count, 3300/mm3, with 56% polymorphonuclear cells, 4% "bands,"
11% monocytes, 26% lymphocytes, and 3% atypical lymphocytes. The
urinalysis was normal; serum creatinine, 0.9 mg/dl; BUN, 32 mg/dl; and
a heterophile test was negative. Liver function tests and serum electro-
lytes were normal. Cultures for bacteria, fungi, and cytomegalovirus
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were negative. Tonsillectomy, performed on the second hospital day,
revealed B-cell lymphoproliferative disease on histologic examination.
Cyclosporine was stopped and the dosages of prednisone and azathio
prine were decreased substantially. A 4-week course of intravenous
acyclovir, 10 mg/kg twice daily, was initiated. A metastatic workup,
including bone marrow biopsy, was negative. No further evidence of
lymphoproliferative disease has been evident. On the less-intensive
immunosuppressive regimen, her renal function has deteriorated slow-
ly; the serum creatinine is 2.5 mgldl one year post transplant.
Patient 3. A 62-year-old man received a cadaveric renal transplant 5
years ago because of ESRD due to diabetic nephropathy. His post-
transplant course was marked by borderline bladder function, which
required prolonged catheterization and Urecholine (bethanechol chlo-
ride) administration. He had undergone a transurethral prostatectomy
prior to renal transplantation. Since receiving the transplant, his renal
function had been excellent (serum creatinine 1.4 mg/dl); he was taking
cyclosporine, 250 mg/day; prednisone, 10 mg/day; and azathioprine,
100 mg/day, and he showed no evidence of rejection. Six months prior
to this admission he underwent an uncomplicated hip replacement.
He was evaluated 5 years after receiving the renal transplant because
of one day of fever and chills, and the sudden onset of oliguria. Physical
examination was remarkable only for a slightly tender renal allograft.
Laboratory evaluation revealed: hematocrit, 34%; white blood cell
count, 9700 mm3, with a normal differential; serum creatinine, 2.4
mg/dl; and BUN, 47 mg/dl. Urinalysis revealed 50—100 leukocytes/high-
power field, as well as yeast forms; subsequent culture of urine and
blood yielded Candida albicans. Ultrasound examination of the renal
allograft disclosed hydronephrosis. Cystoscopy disclosed a gelatinous,
amorphous mass at the ureterovesical junction. The mass was removed,
and placement of a ureteral stent resulted in the immediate output of
large amounts of urine; the serum creatinine level returned to baseline.
Examination of the mass (approximately 5 cm in diameter) revealed a
candidal fungal ball. The patient was treated with fluconazole, 400
mg/day, first intravenously and then orally, without difficulty; his fever
remitted, and blood and urine cultures cleared. The fluconazole was
stopped after 6 weeks. Within one week, asymptomatic candiduria was
noted, and fiuconazole therapy, 200 mg/day, was reinstituted. He now
has received this medication for 9 months without ill effects.
Discussion
DR. ROBERT H. RuBIN (Chief, Infectious Disease for Trans-
plantation; Director, Clinical Investigation Program, Massa-
chusetts General Hospital; and Associate Professor of Medi-
cine, Harvard Medical School, Boston, Massachusetts):
Successful renal transplantation is today's best chance for
rehabilitating individuals with end-stage renal disease. To
achieve this goal, prevention and treatment of infectious dis-
ease complications of transplantation are of major importance
and the requisite immunosuppressive therapy must be judi-
ciously administered. While greater than 95% patient survival
and more than 80% allograft survival at one year are readily
achieved at many transplant centers throughout the world,
more than half of allograft recipients suffer one or more
infections during that first year. Infection remains the leading
cause of morbidity and mortality throughout the post-transplant
course. Therefore, as the cases illustrate, the prevention and
effective treatment of infection remain a major concern of the
transplant clinician. As we approach these issues in this Ne-
phrology Forum, let us consider five basic principles [1].
(1) The presence in the renal transplant recipient of a vascu-
larized organ that differs from the host at a variety of major and
minor histocompatibility loci, the lifetime requirement for
broadly active immunosuppressive therapy, and the presence of
chronic infection with a group of viruses that are themselves
immunomodulating has created a series of clinical phenomena
hitherto unknown in biology and medicine.
(2) Infection and rejection, the two major barriers to success-
ful transplantation, are inextricably linked by the immunosup-
pressive therapy that is being administered. Any intervention
that decreases the risk of rejection and permits the use of
less-intensive immunosuppressive therapy will result in a de-
creased risk of life-threatening infection; any intervention that
decreases the risk of infection and permits the safe use of more
intensive immunosuppressive therapy will decrease the risk of
allograft loss from rejection.
(3) The inflammatory response to microbial invasion in the
transplant patient often is attenuated by concomitant immuno-
suppressive therapy. As a result, not only are the signs and
symptoms of infection frequently blunted, but traditional diag-
nostic approaches to infection, such as skin testing and sero-
logic testing, are rendered significantly less sensitive. Because
the success of therapy in this patient population is predicated on
early diagnosis and initiation of effective therapy, clinicians
must apply invasive diagnostic approaches to seemingly innoc-
uous skin or radiologic findings, and to symptomatic complaints
such as headache or unexplained cough. These diagnostic
approaches include the liberal use of biopsy, and the deploy-
ment of new techniques such as DNA probes (increasingly,
after amplification by the polymerase chain reaction, PCR) and
specific monoclonal antibodies for antigen detection.
(4) Because of the extensive effects of infection in this patient
population, and the difficulties often associated with diagnosis
and treatment, the major goal of the clinician is prevention.
(5) From the perspective of a transplant infectious disease
consultant, the therapeutic prescription for the transplant re-
cipient has two components: immunosuppressive therapy that
prevents or treats allograft rejection, and an antimicrobial
strategy to make immunosuppression safe [21.
Risk
The risk of infection, including opportunistic infection, in the
renal transplant patient is primarily determined by the interac-
tion of two factors: the epidemiologic exposures the patient
encounters and the patient's net state of immunosuppression.
An almost mathematical relationship exists between these two
factors: on the one hand, if the exposure is great enough, even
a normal host with an intact immune system can develop
life-threatening infection; on the other hand, if the net state of
immunosuppression is great enough, even trivial exposures to
organisms in the normal environment can have catastrophic
consequences [1, 31.
The epidemiologic exposures of importance for the transplant
patient can be divided into twO categories—those occurring in
the community, and those occurring in the hospital. Community
exposure poses four major concerns: exposures to the geo-
graphically restricted systemic mycoses (Blastomyces dermati-
tidis, Coccidioides immitis, or Histoplasma capsulatum); My-
cobacterium tuberculosis; Strongyloides stercoralis; and
influenza. In the case of the mycoses and M. tuberculosis,
disseminated disease can result from progressive primary infec-
tion; from reactivation of a long-dormant focus, with secondary
dissemination; or from superinfection, again with dissemina-
tion, as immunosuppression causes a waning of previously
acquired immunity, and as new exposure causes disease.
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Strongyloides stercoralis is the one helminth with an autoinnoc-
ulation cycle in humans; chronic, albeit asymptomatic infec-
tion, can be maintained for decades after an individual was
initially infected (long after the person has left endemic areas
such as Southeast Asia or South and Central America), and
intense and/or disseminated infection can develop after the
initiation of immunosuppressive therapy. In the case of influ-
enza, community-wide outbreaks of this infection can have a
major impact on transplant patients. Thus, evaluation of an
infectious disease syndrome in a transplant patient must include
careful assessment of remote and recent exposures [1, 3].
Of greater concern to the transplant recipient are exposures
within the hospital. Nosocomial epidemics of opportunistic
infection in transplant patients due to Aspergillus species,
Legionella species, and gram-negative organisms such as
Pseudomonas aeruginosa are well recognized. Two epidemio-
logic patterns have been described: domiciliary and
non-domiciliary. Domiciliary exposures occur on the ward
where the patient is housed; these epidemics are characterized
by a clustering of cases in time and space. The provision of
HEPA-filtered air can prevent such events at institutions with
an ongoing problem of this sort. Non-domiciliary exposures
occur when patients are taken to a central facility, such as the
operating room or radiology suite. Such exposures, which often
go undiscovered because of a lack of clustering of cases on a
single ward, are probably more numerous than domiciliary
epidemics. Many non-domiciliary outbreaks are associated with
construction within the hospital environment, and HEPA filters
are not available at many sites. For these reasons, special
masks and transport vehicles that provide a portable source of
HEPA-filtered air have been used in increasing efforts to
protect patients when they travel within the hospital. The
operative principle is that the transplant patient, like other
immunosuppressed hosts, is a "sentinel chicken" within the
hospital environment—any excess traffic in microbes will be
seen first in this patient population, and constant surveillance is
essential to prevent catastrophic outbreaks of life-threatening
infection [4, 5].
The net state of immunosuppression is a complex function
determined by the interaction of a number of factors, the most
important of which are the dose, duration, and temporal se-
quence in which immunosuppressive drugs are deployed. Other
factors that contribute to the net state of immunosuppression
include the following: the presence of leukopenia, injury to the
mucocutaneous surfaces of the body, or foreign bodies (for
example, as urinary catheters); metabolic abnormalities such as
malnutrition, uremia, and, perhaps, hyperglycemia; and infec-
tion with one or more of the immunomodulating viruses,
cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis B
and C viruses (HBV and HCV, respectively), as well as the
human immunodeficiency virus (HIV). Two observations from
our own experience underline the importance of some of these
factors in determining the net state of immunosuppression:
First, when renal transplant patients receiving similar immuno-
suppressive regimens are stratified on the basis of the serum
albumin level being greater or less than 2.8 g/dl, one can see that
those with the lower level have a tenfold higher incidence of
developing life-threatening infection. Second, approximately
90% of patients who develop opportunistic infection due to
organisms such as Aspergillus species or Legionella species
after renal transplantation do so during or shortly after immu-
nomodulating viral infection. Indeed, virtually the only excep-
tions to this rule are patients who have acquired their infection
as a result of an unusually intense environmental exposure,
usually within the hospital [1, 3].
Timetable of infection
The immunosuppressive regimens currently employed are
accompanied by a well-defined temporal sequence of infections
(Fig. 1). Infectious disease syndromes, pneumonia, for exam-
ple, can occur at any point in the post-transplant course, but the
microbial cause varies tremendously with time. Exceptions to
this temporal sequence usually connote an unusual epidemio-
logic hazard. In the renal transplant patient, it is useful to divide
the post-transplant period into three parts [1, 3].
(1) First month post transplant. In this time period, more than
95% of infectious disease syndromes are the same bacterial or
candidal wound infections, postoperative pneumonias, and
intravenous- or urinary catheter-related infections that occur in
nonimmunosuppressed patients undergoing similar kinds of
surgery. All these infections result from technical complications
from the surgery, or from the management of the endotracheal
tube, intravenous line, or bladder catheter. All underline the
principle that a technical mishap invariably leads to infection in
immunosuppressed patients. Unusual causes of clinical infec-
tion during this period are (a) re-emergence of an infection that
was not eradicated before transplantation, and which is ren-
dered more pathogenic by surgery and subsequent immunosup-
pression; and (b) active infection conveyed with the allograft.
Contamination of the allograft with Staphylococcus aureus,
Candida species, or gram-negative bacilli such as Pseudomonas
aeruginosa results in life-threatening infection post transplant,
often presenting catastrophically with a rupture of a mycotic
aneurysm at the vascular suture line. Because of this risk,
potential donors are carefully evaluated for the presence of
bacteremic infection that could contaminate the allograft.
The fact that opportunistic infections are not present in the
first month after transplantation, when the dose of immunosup-
pressive drugs is at its highest, emphasizes that it is the duration
of immunosuppression, the "area under the curve," rather than
the daily dosage administered, that is the major determinant of
the net state of immunosuppression. The rare occasions when
opportunistic infections do occur during this "one-month
golden period" present prima facie evidence of an unusually
intense environmental exposure (usually within the hospital)
and usually with the potential for causing a mini-epidemic in
this patient population.
(2) One to six months post transplant. The causes of infection
during this period are very different from those during the first
4 weeks post transplant. By far, the most important cause of
infectious disease syndromes in this period (as exemplified by
the first 2 patients presented) are the immunomodulating vi-
ruses. For example, CMV itself is the cause of more than
two-thirds of febrile episodes during this time [1, 3]. In addition
to directly causing infectious disease syndromes, these viruses
combine with the sustained administration of immunosuppres-
sive drugs to produce a greater net state of immunosuppression,
a level that permits the occurrence of opportunistic infection
due to organisms such as Pneumocystis carinii, Listeria mono-
cyto genes, and Aspergillus fumigatus.
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(3) More than six months post transplant. Patients with a
functioning allograft, virtually all of whom continue to receive
immunosuppressive therapy more than 6 months post trans-
plant, can be divided into three groups. (a) Approximately 75%
of these patients have good allograft function, are receiving
minimal maintenance immunosuppressive agents, and are free
of chronic viral infection. The infections these patients develop
are similar to those observed in the general population—
influenza, pneumococcal pneumonia, urinary tract infection,
etc. (b) Approximately 10% to 15% have chronic viral infection
with CMV, EBV, the hepatitis viruses (HBV or HCV), or HIV,
which inexorably lead to organ failure (chorioretinitis from
CMV, cirrhosis from HBV or HCV), malignancy (lymphopro-
liferative disease from EBV; hepatocellular carcinoma from
HBV and, possibly, HCV; and possibly other viral—associated
malignancies such as squamous cell carcinoma from papilloma-
virus), or the acquired immunodeficiency syndrome (AIDS).
The general rule is that immunosuppressive therapy stimulates
proliferation of these viruses, and the host defenses of these
patients are unable to clear these infections. (c) Finally, 5% to
15% of patients, who are characterized by relatively poor
allograft function (serum creatinine levels >2.7 mgldl), a history
of acute and chronic rejection, and an excessive amount of
immunosuppression, are at highest risk for opportunistic infec-
tions such as those caused by Cryptococcus neoformans,
Pneumocystis carinii, Listeria monocytogenes, or Nocardia
asteroides.
From a different perspective, we clearly can divide the
infections that occur in transplant patients into three general
categories: those related to technical complications; those
related to intensive epidemiologic exposures; and those related
to viral infections (Table 1).
Viral infections
Viral infections are the single greatest cause of infectious
disease morbidity and mortality in transplant recipients [1, 3].
Fig. 1. Timetable for the occurrence of
infection in renal transplant recipients.
(Modified from Ref. 3.)
On the one hand, transplant patients remain susceptible to
common viral infections such as influenza. On the other hand,
certain viruses—notably the herpes group viruses, the hepatitis
viruses, and HIV—have a higher attack rate, a faster rate of
disease progression, and a broader range of clinical effects in
transplant patients than they do in other patient populations
(Table 2).
Of all the viruses, the herpes group viruses (CMV, EBV,
varicella-zoster virus [VZV], herpes simplex virus types 1 and
2 [HSV- 1 and HSV-2], and human herpesvirus-6 [HHV-6]) are
the most important causes of infectious disease morbidity and
mortality for the transplant recipient. Their hazard is largely
due to three properties of all herpes viruses: latency, cell
association, and oncogenicity. The term "latency" is used to
designate the fact that, once infected with these viruses, an
individual is infected for life, even after evidence of active viral
replication is no longer demonstrable. Latent virus can be
reactivated at a later date; the stability of latency and the
factors that will reactivate the virus are different for each of
these viruses, although all are reactivated by immunosuppres-
sive drugs. The laboratory marker for the presence of latent
infection is the presence of circulating antibody ("seropositiv-
ity") in the absence of active viral replication. "Cell associa-
tion" means that the virus is transmitted between individuals
and spread within an individual by cell-to-cell contact, render-
ing humoral immunity inefficient and cell-mediated immunity
essential as the host defense against these viruses. The key host
defense against herpes-group viruses is mediated by virus-
specific, MHC-restricted, cytotoxic T-cells. Unfortunately,
these cells are most susceptible to cyclosporine-based immu-
nosuppressive regimens. Finally, all herpes-group viruses are
potentially oncogenic, with EBV-associated lymphoprolifera-
tive disease providing the clearest evidence of this possibility
[1, 6].
Cytomegalovirus. Cytomegalovirus is the most important
single microbial pathogen among renal transplant recipients.
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Table 1. Classification of infections occurring in transplant patientsa
Infections related to technical complications"
Transplantation of a contaminated allograft
Anastomotic leak or stenosis
Wound hematoma
Intravenous line contamination
latrogenic damage to the skin
Mismanagement of endotracheal tube leading to aspiration
Infections related to excessive nosocomial hazard
Aspergillus species
Legionella species
Pseudomonas aeruginosa and other gram-negative bacilli
Nocardia asteroides
Infections related to particular exposures within the community
Systemic mycotic infections in certain geographic areas
Histoplasma capsulatum
Coccidioides immitis
Blastomyces dermatitidis
Strongyloides stercoralis
Community-acquired opportunistic infection resulting from
ubiquitous saprophytes in the environmente
Cyptococcus neoformans
Aspergillus species
Nocardia asteroides
Pneumocystis cannii
Respiratory infections circulating in the community
Mycobacterium tuberculosis
Influenza
Adenoviruses
Infections acquired by the ingestion of contaminated food or water
Salmonella species
Listeria monocytogenes
Viral infections of particular importance in transplant patients
Herpes group viruses
Hepatitis viruses
Human immunodeficiency virus (the causative agent of acquired
immune deficiency syndrome)
a Modified from Ref. 1.
b All lead to infection with gram-negative bacilli, Staphylococcus
species, and/or Candida species.
C The incidence and severity of these infections and, to a lesser
extent, the other infections listed, are directly related to the net state of
immunosuppression present in a particular patient.
Evidence of CMV infection is found in at least two-thirds of
these patients, although clinical disease is found in a much
smaller number. The major determinants of CMV infection in
this patient population are the presence of latent virus (that is,
seropositivity) and the type of immunosuppressive therapy
being administered. As far as the first determinant is concerned,
three epidemiologic patterns of CMV infection are observed
among renal transplant recipients [1, 7].
Primary infection occurs when latently infected cells are
transmitted from a seropositive donor to a seronegative recip-
ient. Among renal transplant recipients, latently infected cells
are conveyed with the allograft more than 90% of the time,
although viable leukocyte-containing blood products also can
transmit the virus. Approximately 60% of seronegative patients
become symptomatic with CMV disease [8, 9]. Of interest, it is
now apparent that when kidneys from a seropositiye donor are
placed into two seronegative recipients, either both recipients
develop symptomatic infection or neither do. Unfortunately,
currently available serologic or other laboratory tests are un-
able to distinguish between the seropositive donors who trans-
mit infection and those who do not [10].
Table 2. Clinical effects of viruses in the renal transplant recipient
Direct effects
Direct causation of such infectious disease clinical syndromes as
mononucleosis, hepatitis, pneumonia, gastrointestinal ulcerations,
etc
Indirect effects
Contribute broadly to the net state of immunosuppression, thus
predisposing to opportunistic infection with opportunistic
pathogens such as Pneumocystis carinii, Aspergillus fumigatus,
and Listeria monocytogenes
May contribute to the pathogenesis of allograft injury
May play a role in oncogenesis
Reactivation infection occurs when seropositiye individuals
reactivate their endogenous latent virus. It is currently esti-
mated that approximately 20% of these individuals become
symptomatic, but this figure is strongly influenced by the
immunosuppressive therapy being administered [11]. The titer
of neutralizing antibody present in seropositive individuals does
not predict either the occurrence of symptomatic disease or the
gravity of clinical disease if it develops [12].
Sunerinfection occurs when seropositive recipients receive
an allograft from a seropositive donor, and the reactivated virus
is of donor rather than recipient origin. Evidence of superinfec-
tion (as delineated by molecular virologic techniques) can be
found in at least 50% of instances in which a kidney from a
seropositive donor is transplanted into a seropositive recipient.
What is currently less clear is whether this event, and the
well-known genomic and antigenic diversity that occurs among
cytomegalovirus isolates, has a greater clinical impact than
does endogenous reactivation. The incidence of clinical disease
in this group is probably 20% to 40%, but again the incidence is
modified by immunosuppressive therapy [11, 13, 14].
Clinical observations over the past two decades have shown
that when anti-lymphocyte antibody therapy was added to
conventional immunosuppression (whether azathioprine and
prednisone in the 1970s, or cyclosporine, low-dose prednisone,
with or without azathioprine from 1984 to the present), CMV
disease increased strikingly. In this regard, it does not seem to
matter whether the anti-lymphocyte antibody preparation em-
ployed is polyclonal (for example, anti-thymocyte globulin and
anti-lymphocyte serum) or monoclonal (for example, OKT3) [7,
11, 15—17]. One change has occurred, however: in the l970s,
relapsing infection was rarely seen, but in the l990s, 15% to
20% of patients with symptomatic CMV relapse after they
seemingly have responded to a therapeutic course of the
antiviral drug ganciclovir [7].
Recent studies in the murine CMV model and in human
transplant recipients provide a plausible explanation for these
observations and reemphasize the importance of immunosup-
pression in modulating the effects of this virus. When equiva-
lent antirejection regimens of cyclosporine, anti-thymocyte
globulin, anti-CD3 monoclonal antibody, rapamycin, or other
immunosuppressive agents are administered to mice with either
latent or active infection, very different effects are observed.
Whereas cyclosporine, rapamycin, and corticosteroids cannot
reactivate latent virus, the antilymphocyte antibodies readily
can; cytotoxic drugs such as cyclophosphamide and azathio-
prine are moderately potent in reactivating latent virus. In
226 Nephrology Foru,n: I.D. complications of renal transpiantion
contrast, after active, replicating virus is present, cyclosporine,
and to a lesser extent, rapamycin, are far more potent in
promoting viral replication and dissemination than are the
anti-lymphocyte antibodies. Not surprisingly, then, the se-
quence in which immunosuppressive therapy is administered
has an important effect on the course of CMV infection. The
most dangerous scenario, unless an effective antiviral strategy
is employed, is the reactivation of virus by anti-lymphocyte
antibody therapy, followed by a cyclosporine-based immuno-
suppressive regimen that blocks the host's response to the now
active virus [7, 11].
Recent observations in CMV-seropositive renal transplant
recipients are consistent with these experimental results. When
these patients receive only cyclosporine-based immunosup-
pression after transplantation, the incidence of overt disease
ranges between 10% and 20%. When OKT3 or polyclonal
anti-lymphocyte antibody therapy is added to the program, the
incidence of overt disease rises to approximately 60%. Thus it
appears that the host's ability to limit the replication of even
small amounts of virus is blunted by current cyclosporine-based
immunosuppressive regimens. This phenomemon presumably
also explains the occurrence of relapsing disease after ganciclo-
vir therapy.
The direct clinical effects of CMV in the renal transplant
recipient can be divided into two categories: (1) the acute
effects that appear one to four months post transplant (as in the
first patient presented), and which consist of varying combinations
of fever, leukopenia, thrombocytopenia, pneumonia, hepatitis,
and gastrointestinal ulcerations; and (2)progressive chorioreti-
nitis, which presents more than six months post transplant, and
which can follow earlier acute disease or can be the first
manifestation of CMV infection (11.
The most important infectious disease effect of CMV infec-
tion, however, is its broad-based suppressive effect on host
defenses that can lead to opportunistic superinfection [1, 71. Of
particular interest is the linkage between CMV and Pneumo-
cystis carinii pneumonia. This association appears at least in
part related to the key role of alveolar macrophages in control-
ling Pneumocystis and to the marked inhibitory effect CMV has
on the function of this group of cells [1, 7, 18]. Other host
defense defects associated with CMV infection in transplant
patients include neutropenia, depressed natural killer (NK) cell
and monocyte function, and hyporeactivity of lymphocytes
studied in vitro 11, 71.
By far the most controversial aspect of CMV infection is the
possibility that the virus adversely affects allograft survival.
Since Simmons and colleagues first raised this possibility in
1970 [19], proving this hypothesis has been difficult, largely
because of a lack of a laboratory marker for distinguishing
trivial from clinically important CMV infection. Results from
several epidemiologic studies are consistent with this hypothe-
sis, but the "smoking gun" is still missing [20—26]. In 1981
Richardson et al described a unique form of glomerular lesion
that was associated with CMV viremia [27]. Subsequent studies
by this group have shown that this glomerular lesion was
associated with the same change in circulating T-cell subsets
(increased CD8 cells, decreased CD4 cells, and a "reversed
CD4/CD8 ratio") that occurs in systemic herpes-group virus
infection. Further, unlike the situation with classical rejection,
in these patients the glomerular lymphocytic infiltrate was
shown by biopsy to have the same "viral like" preponderance
of CD8 cells [28, 291. Other groups agree that such a lesion
exists, but that the association with CMV is at best tenuous [30,
31]. Recent studies in which CMV infection has been associated
with allograft damage in other transplant populations (acute and
chronic cardiac allograft injury, bronchiolitis obliterans in lung
allografts, and an unusual histologic pattern of injury in liver
allografts) has strengthened the argument that CMV infection
shortens allograft survival [7, 32].
If CMV does indeed adversely affect the renal allograft, by
what mechanisms does it do so? Two major hypotheses, not
mutually exclusive, have been suggested. The first of these,
which notes the homology between certain CMV antigens and
histocompatibility antigens, is "molecular mimicry." That is,
an immune response, directed against CMV, also recognizes
homologous histocompatibility antigens and causes allograft
damage. The second hypothesis, which I favor, is that the
effects of the virus are indirect. That is, the ubiquitous cyto-
kines, such as the interferons, elaborated in response to CMV
infection, stimulate the display of histocompatibiity antigens
on the allografted tissue, thus stimulating immune recognition
of differences between donor and recipient and increasing the
potential for immune attack of the allograft. The fact that other
processes could have effects on cytokine production might
explain the lack of association of CMV with the glomerulo-
pathic lesion reported by some authors [1, 7, 32].
Given the protean manifestations of CMV, some proved and
others controversial, it is not surprising that extensive efforts
have been made both to treat and prevent CMV infection
[33—36]. Intravenous ganciclovir (at a dose of 5 mg/kg twice
daily for 2 to 3 weeks) is quite effective in treating symptomatic
disease [1, 7]. Studies in the murine CMV model and the
experience with bone marrow transplant patients with CMV
pneumonia suggest that CMV hyperimmune globulin added to
the therapeutic regimen is beneficial in patients with severe
CMV disease, particularly pneumonia, and in patients with
relapsing disease. Indeed, the first patient presented here was
given both ganciclovir and hyperimmune anti-CMV immuno-
globulin and recovered. Although ganciclovir-resistant CMV
infection is not an uncommon event in AIDS patients, and
necessitates foscarnet therapy, this problem has not arisen in
renal transplant recipients, and experience with foscarnet in
this clinical setting is minimal [1, 2, 7].
Of course, prevention of CMV disease would be ideal.
Providing kidneys from seronegative donors to seronegative
recipients is theoretically an effective way of preventing pri-
mary disease. Because of the limitations that such a strategy
would place on the use of an already inadequate supply of
donors, however, it is more desirable to develop an effective
antiviral strategy [1]. High-dose oral acyclovir (approximately
3200 mg/day for 4 to 6 months) and hyperimmune CMV
immunoglobulin (and possibly unselected intravenous immuno-
globulin) given 6 to 12 times over a 4- to 6-month period are
moderately effective in preventing CMV disease [35]. But both
these regimens suffer from several disadvantages: great ex-
pense, logistic inconvenience, and an attenuation of efficacy in
the presence of anti-rejection therapy with anti-lymphocyte
therapy. The Halifax group reported in abstract that giving
lower doses of both these agents, as in the murine model, is
probably more effective than giving either alone [36], but again,
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benefit is diminished if anti-lymphocyte antibody therapy is
required. We have taken a different approach, administering a
"pre-emptive" course of ganciclovir during anti-lymphocyte
antibody treatment; this intervention produces significant im-
provement, reducing the incidence of symptomatic disease at
least threefold [11].
Recent advances in CMV detection, directly demonstrating
CMV antigens in blood or CMV viremia by polymerase chain
reaction, can provide diagnostic information on a same-day
basis. Since viremia can be detected by PCR or antigenemia
assays several days before clinical disease appears, the initia-
tion of pre-emptive therapy has a great deal of appeal [37]. A
similar strategy, that is, early detection of viremia prompting
pre-emptive ganciclovir therapy, offers great promise in pre-
venting CMV pneumonia in bone-marrow-transplant recipients
[38]. I think that the anti-CMV strategy of the future will consist
of a baseline prophylactic program, particularly for patients at
risk for primary disease, with the provision of additional
treatment if intensive antirejection therapy is required, with
pre-emptive therapy added on the basis of the laboratory
monitoring for viremia that I already noted. This approach
might have prevented the CMV disease in today's first patient
[2].
Epstein-Barr virus. Many of the clinical manifestations of
EBV in the renal transplant patient are obscured by the ubiquity
of CMV in this patient population and the fact that these closely
related viruses can cause similar clinical syndromes. Thus, it is
clear that a mononucleosis syndrome characterized by fever,
leukopenia, mild hepatitis, atypical lymphocytosis (usually no
more than 5% to 10% of circulating leukocytes), a change in
circulating T-cell subsets to a "reversed CD4/CD8 ratio," and a
negative heterophile can be caused by EBV as well as by CMV.
The EBV syndrome in the transplant patient differs from
EBV-induced mononucleosis in the normal host by the lack of
a positive heterophile test, the low level of atypical lympho-
cytes and, usually, the absence of splenomegaly and pharyngi-
tis. The frequency with which EBV, as opposed to CMV, is the
cause of this syndrome is unclear, and the frequency and effects
of dual infection are equally unclear at present [1, 39]. For
example, does infection with these two viruses have more
severe acute or more longer-lasting effects than does infection
with either alone?
What is abundantly clear, however, is the critical role of EBV
in the pathogenesis of EBV-associated lymphoproliferative
disease. So-called reticulum cell sarcoma, particularly that
affecting the central nervous system, has been recognized as an
unusual complication of immunosuppressive therapy for de-
cades [1]. It typically presented more than 2 years post trans-
plant in patients receiving azathioprine-based immunosuppres-
sion. But since the advent of cyclosporine and the wider use of
anti-lymphocyte antibody anti-rejection therapy, the incidence
of this entity has steadily grown [1, 40—44].
The normal site of EBV proliferation is in pharyngeal epithe-
hal cells. Secondary infection of B-lymphocytes via the C3d
complement receptor on these cells then results in their trans-
formation and "immortalization" [45, 46]. In the normal host,
either the development or the presence of MHC-restricted,
EBV-specific, cytotoxic T-cells acts as a surveillance mecha-
nism that destroys these immortalized B-cells, thus interrupting
the oncogenetic process [1, 41, 42]. This mechanism develops in
patients with primary EBV infection, and is present in patients
seropositive for EBV (more than 95% of the adult population in
the United States). In CMV infection, latency is stable and
requires certain forms of immunosuppression, an allogeneic
reaction, or pregnancy to reactivate it. The latency of EBV,
however, is very unstable. Thus EBV can be isolated from
pharyngeal secretions of 20% of normal individuals at any point
in time and from approximately 30% of transplant patients. In
transplant patients receiving anti-lymphocyte antibody therapy,
the incidence of EBV replication in the pharynx rises to 70% to
80%, thus increasing the potential for secondary infection of
B-cells [47, 48]. Cyclosporine, in a dose-dependent fashion,
blocks the surveillance mechanism that generally eliminates the
transformed B-cells. To a lesser extent, other components of
the immunosuppressive program also block that mechanism,
adding to the risk of oncogenesis. As with CMV, the worst
possible scenario is to use anti-lymphocyte antibody therapy
first, which increases the amount of viral replication, and then
block the response with cyclosporine-based immunosuppres-
sion in the absence of a corresponding escalation in the antiviral
program [2]. This likelihood is magnified in individuals, partic-
ularly children, who have primary EBV infection. The attack
rate for lymphoproliferative disease thus is highest in patients
with primary EBV, as in the second patient presented. Still,
since the great majority of patients undergoing transplantation
are seropositive, most cases of lymphoproliferative disease
occur in adults with reactivation EBV disease [49].
Recent observations by Preiksaitis et at shed further light on
these events [48]. Careful quantitative EBV cultures of pharyn-
geal secretions carried out serially revealed two important
observations. (1) Lymphoprohiferative disease developed in the
subgroup of individuals who had the greatest amount of viral
replication, which itself was related, as previously noted, to
immunosuppressive therapy. (2) Replication of EBV could be
interrupted by antiviral therapy with either acyclovir or ganci-
clovir. These findings suggest the possibility of a preventive
antiviral strategy similar to that outlined for CMV, with a
particular emphasis on pre-emptive antiviral therapy during
periods of increased immunosuppression, especially with anti-
lymphocyte antibody preparations.
A variety of clinical presentations of EBV lymphoprohifera-
tive disease have been noted: tonsillitis (as in the second patient
presented), fever of unknown origin, hepatocellular dysfunc-
tion, focal brain or pulmonary disease, focal gastrointestinal
disease presenting as GI bleeding or perforation, and focal
disease invading the allograft itself. The important point to
remember is that, unlike more typical lymphomas, EBV-asso-
ciated lymphoproliferative disease frequently has an extranodal
presentation [1]. We have observed patients with no evidence
of adenopathy on abdominal or chest CT scan despite the
presence of focal disease involving the allograft, liver, small
bowel, and brain.
Clinically and pathologically, EBV-associated lymphoprolif-
erative disease runs the gamut from a polyclonal, clearly benign
process (just a "bad case of mono") to a monoclonal, rapidly
progressive, highly malignant process. Unfortunately, as the
second patient illustrates, we have no good markers to distin-
guish benign from highly malignant disease. Pathologic demon-
stration of cellular atypicality, clonality, chromosome abnor-
malities, and the like have not yet been correlated with clinical
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outcome in the individual patient, at least in part because many
of these processes are not uniform, with monoclonality in some
areas and polyclonality in others [1, 44]. Although some inves-
tigators have suggested that these patients only need a cessation
or reduction in immunosuppression—particularly cyclospo-
rine—to allow the surveillance mechanism to eliminate the
EBV-transformed B-cells [50], in our experience these lesions
regress in only 20% of patients in whom this approach plus
high-dose acyclovir therapy is tried. Today's second patient,
fortunately, is one of the lucky few who responded to this
approach. The value of administering acyclovir after the lym-
phoproliferative disease has developed is debatable, as the
process appears to be EBV-independent at this point. The value
of chemotherapy, radiation therapy, or an anti-B-cell mono-
clonal-antibody-based therapy for patients who don't respond
to simple measures is not known at present. Clearly, EBV-
associated lymphoproliferative disease is far better prevented
than treated [1, 441.
Varicella-zoster virus. Primary VZV infection in the renal
transplant patient can have disastrous consequences: dissemi-
nated visceral infection, hemorrhagic pneumonia, encephalitis,
disseminated intravascular coagulation, and, if untreated,
death. Because this syndrome is potentially catastrophic, and
because high-dose intravenous acyclovir is so effective in
treating it early in the course, clinicians, patients, and patients'
families must be highly vigilant of this infection. This alertness
begins with screening all transplant candidates (or recipients, if
the information is not already known) for antibody to VZV.
Seronegative individuals are at risk for primary infection and
should receive zoster immune globulin for any exposure to the
virus. Even having given the patient this passive protection, the
clinician must recognize that failures occur, particularly if there
has been a delay in the administration of the globulin after
exposure. Failure of passive immunization can produce an
altered clinical presentation, with multi-organ involvement in
the absence of the typical vesicular lesions of primary VZV
infection. Pediatric renal transplant recipients often can be
exposed to chicken pox in school and elsewhere, and these
children can require many doses of the globulin. Hopefully, the
new varicella vaccine will make possible active immunization in
VZV-seronegative patients [51].
In direct contrast to the virulence of primary VZV infection
in transplant patients is the relative benignity of reactivated
VZV infection among renal transplant patients. Typical zoster,
involving 1 to 3 dermatomes and occasionally presenting with
some cutaneous dissemination, occurs in 20% to 30% of trans-
plant patients. Visceral dissemination is quite unusual in this
patient population, however, and antiviral therapy is not always
required [11.
Herpes simplex virus. Significant and recurrent oro-facial
(due primarily to HSV-l) or ano-genital (due primarily to
HSV-2) herpetic infection occurs in as many as 50% of renal
transplant recipients [1, 6]. As with other herpes-group viruses,
this incidence figure is strongly influenced by the immunosup-
pressive therapy being administered. The vast majority of these
infections are of the reactivation type, with disseminated dis-
ease rarely observed. Disseminated primary infection has rarely
been noted as well. In renal transplant patients, reactivation
HSV infections differ from those in normal individuals in
several ways: ulceration is often more prominent than vesicle
formation; disease recurs more often; and acyclovir therapy
confers a clearer clinical benefit [1]. Again, like CMV infection,
acyclovir-resistant HSV infection has not been an important
problem in this patient population, as opposed to patients with
AIDS. Uncommon manifestations of HSV infection in renal
transplant patients include a zosteriform rash, often recurrent,
and usually in a sacral dermatome; and eczema herpeticum
(Kaposi's varicelliform eruption), a disseminated cutaneous
form of HSV infection that usually occurs at sites of previous
skin injury. Oral or intravenous acyclovir is effective in treating
HSV infection in this patient population. The oral dose is 200
mg five times per day for 7 to 14 days, or longer if immunosup-
pression is being intensified; intravenous administration re-
quires 5 mg/kg every 8 hours for a similar period. For patients
with frequent recurrences, oral acyclovir prophylaxis is effec-
tive. Ganciclovir is as effective in the treatment of HSV as is
acyclovir, so both drugs are not needed at the same time in
patients with dual infection with HSV and CMV [1, 15, 52—54].
Human herpesvirus-6. In some ways, HHV-6 in transplant
patients is an "orphan virus"; that is, evidence of viral repli-
cation is common in this patient population, but the clinical
effects of this event currently are not well understood [1, 55].
Hepatitis. The incidence of chronic liver disease among renal
transplant recipients is approximately 10% to 15%. Liver dis-
ease is the cause of death in 8% to 28% of individuals surviving
more than 10 years post transplant [56, 57]. Although drug-
induced hepatic toxicity from agents such as cyclosporine,
azathioprine, isoniazid, and rifampin occasionally is observed,
and should always be sought, the major causes of liver disease
in the renal transplant patient are hepatitis B and hepatitis C
[56].
Transplantation of an organ from an HBV carrier is a very
efficient means of transmitting this virus. The laboratory marker
is the presence of hepatitis B surface antigen [HBsAg]. The
sensitivity of current HBsAg screening methods has made the
peritransplant acquisition of HBV a rare event, on the order of
0.002% of transplants, where adequate testing standards are
employed. This prevention of illness is fortunate, because
acquisition of HBV during transplantation is associated with a
markedly increased risk of fulminant hepatitis [56]. More prob-
lematic is the allograft recipient who already is chronically
infected with this virus. Although virus replication often de-
creases in the normal host, immunosuppressive therapy ap-
pears to directly stimulate viral replication. This effect is
reflected in a prompt increase in hepatitis B virus DNA poly-
merase activity, HBeAg, and hepatitis B virus DNA, as well as
HBsAg, that occurs shortly after the initiation of immunosup-
pressive therapy. Moreover, increased viral replication often is
associated with progressive liver disease, despite a paradoxical
apparent improvement in biochemical measurements of liver
injury, for example, aminotransferase levels [56, 58—60]. Onco-
genesis also is facilitated by this increase in viral replication,
perhaps through the product of the HBx gene, a viral transac-
tivator, which can induce liver cancer in transgenic mice [61].
The clinical effects of hepatitis B virus infection must be
considered in two time frames. In the first one to two years after
transplantation, hepatitis B infection contributes to the net state
of immunosuppression, but clinical manifestations of chronic
liver disease usually are not apparent. After two years, how-
ever, renal transplant patients with chronic HBV infection
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develop inexorably progressive chronic liver disease, hepato-
cellular carcinoma, or both [56]. For example, Rao and Ander-
son reported on a large group of patients with chronic hepatitis
B infection 10 years after renal transplantation [62]. In this
study, 38% of the patients had chronic progressive hepatitis,
38% had chronic active hepatitis, 42% had cirrhosis, and 54%
died of liver failure. These data contrast with those from
patients with chronic liver disease but without hepatitis B virus
infection (presumably the liver disease was due to hepatitis C
infection), where the findings were 17% with chronic progres-
sive hepatitis, 14% with chronic active hepatitis, 19% with
cirrhosis, and 12% with death due to liver failure. It appears
that the subgroup of HBsAg-positive candidates who do partic-
ularly poorly after transplantation are those who are HBeAg
positive or who have histologic findings of ongoing hepatitis at
the time of transplantation [63]. The McGill group has made a
strong argument that the mortality rate of HBsAg-positive
individuals post transplant is significantly higher than the rate
had they remained on dialysis; other groups disagree [64—68].
Our policy has been to regard a positive HBsAg test in a renal
transplant candidate as a relative, but not absolute, contraindi-
cation to transplantation, with such other factors as liver
histology, level of viral replication (HBeAg, HBV DNA, etc.),
level of nutrition, other illnesses, quality of life, and the
patient's wishes entering into the decision making. Unfortu-
nately, alpha-interferon therapy of hepatitis B infection in the
transplant recipient appears to be less effective than in the
normal population, and this approach might have adverse
effects on allograft function [56].
Hepatitis C virus, which accounts for virtually all cases of
non-A, non-B hepatitis in developed countries, is the major
cause of hepatitis and chronic liver disease in renal transplant
recipients, and might also be related to the development of
hepatocellular carcinoma [1, 69]. As in the general population,
the major concern in the renal transplant patient is the acquisi-
tion of chronic hepatic disease; more than 20% of renal trans-
plant patients who develop evidence of hepatitis after transplan-
tation clear their infection [691. Recent studies by Pereira et al
have shed considerable light on the epidemiology of HCV
infection in this patient population [70, 71]:
(1) Even second-generation assays for anti-hepatitis C virus
underestimate both the presence of virus in potential donors
and the acquisition of infection by transplant recipients. For
example, only 62% of patients with HCV infection acquired at
transplantation developed anti-HCV antibodies.
(2) Studies in which first-generation anti-HCV assays were
used retrospectively to study donor sera suggested that about
one-half of the recipients of organs from anti-HCV-positive
donors developed hepatitis post transplant [70, 71]. More recent
studies in which the polymerase chain reaction demonstrated
the presence of hepatitis C virus RNA in serum specimens have
re-emphasized the risk of HCV transmission by an infected
allograft [70, 71]. When an organ from an HCV-RNA-positive
donor was transplanted into an HCV-RNA-negative recipient,
the incidence of post-transplant hepatitis C virus infection was
100% [70, 71].
(3) Although still controversial, the recommendations of the
U.S. Public Health Service to limit the use of organs from
anti-HCV-positive donors for only "life-saving procedures"
(defined as liver, heart, or lung transplants) and not for renal
transplants [72] appear reasonable. Evidence is accumulating
that more than one strain of hepatitis C virus might exist, and
that anti-HCV might not confer immunity to further infection.
Thus I believe that even the strategy of transplanting kidneys
from HCV-positive donors into anti-HCV-positive recipients
currently must be regarded as questionable [711.
The clinical expression of hepatitis C virus in the transplant
recipient is slowly progressive liver disease. Acute, symptom-
atic hepatitis rarely develops. In the first 2 to 3 years, HCV
infection contributes to the net state of immunosuppression;
after 3 years, progressive liver disease develops, although at a
slower rate than disease from hepatitis B virus. As with HBV,
however, effective anti-viral therapy in this clinical setting is
still in its infancy [56, 69].
Human immunodeficiency virus. As in most areas of medi-
cine, HIV infection is beginning to have an impact on organ
transplantation as well. The transplantation of an organ from an
HIV-infected donor is virtually certain to transmit this infec-
tion; the rate of transmission approaches 100% [1]. With
currently available techniques for screening prospective do-
nors, we should be able to prevent the primary acquisition of
HIV at transplantation for virtually all recipients. Let me
proffer one caution, however: the blood sample tested should
be the potential donor's own blood, not transfused blood. In
one tragic example, a motor vehicle accident victim who
received more than 50 units of blood products prior to being
evaluated as a potential donor transmitted HIV infection to the
organ recipients. The HIV test on a blood sample drawn post
transfusion was negative [1].
A growing question is the appropriate management of pa-
tients with end-stage renal disease, who otherwise are good
candidates for renal transplantation, but who are asymptomatic
carriers of HIV. Currently available information from all forms
of organ transplantation suggests that HI V-positive individuals
undergoing organ transplantation comprise three approximately
equal groups in terms of clinical outcome: one-third do very
poorly, dying within 6 months of transplantation, primarily of
infection; one-third have an intermediate result, developing
AIDS 2 to 3 years after transplantation, although zidovudine
therapy and anti-pneumocystis prophylaxis can extend mean-
ingful life; and one-third do very well and are asymptomatic
with functioning allografts 5 to 7 years post transplantation.
Based on these data, and the availability of dialysis to extend
life, our policy is not to perform renal transplantation in
HIV-infected individuals, although we do consider liver or
cardiac transplantation for HIV-infected patients with end-
stage liver or heart disease, for whom alternative means for
preserving life currently are not available [1].
Bacterial infection
Bacterial infections in the renal allograft recipient can be
divided into three general categories: those due to the usual or
common infectious bacteria; those due to Mycobacteria spe-
cies; and those due to opportunistic bacterial species such as
Listeria monocytogenes and Nocardia asteroides [1].
By far the most common form of bacterial infection in renal
transplant recipients is urinary tract infection (UTI). Without
antibiotic prophylaxis, the reported incidence of UTI is 35% to
79%, with 60% of the gram-negative bacteremias in this patient
population stemming from the urinary tract [1, 73—75]. The
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bacteria causing UT! in renal transplant patients are similar to
those causing UTI in the general population: enterobacteri-
aceae, particularly Escherichia coil, enterococci, and Pseudo-
monas aeruginosa. As with other forms of infection in the renal
transplant patient, the timing of infection is important in deter-
mining the clinical impact. Urinary tract infections beginning
more than 6 months post transplant, in the absence of an
anatomic abnormality such as a stone, usually are benign, can
be managed with a conventional 10- to 14-day course of
antibiotics, and rarely are associated with bacteremia or require
hospitalization. In contrast, urinary tract infections presenting
in the first few months after transplantation frequently are
associated with overt pyelonephritis, bacteremia, and a high
rate of relapse when treated with a conventional course of
antibiotics [1, 73].
The pathogenesis of bacterial invasion of the kidney in the
first 6 months after transplantation appears to be as follows.
Bacteria are introduced via the bladder catheter inserted at the
time of transplantation; a high rate of bacterial invasion exists
because of the kidney's vulnerability following surgical manip-
ulation and "immunologic injury"; and tissue infection is
potentiated by the immunosuppresssive therapy [1].
Over the past decade, clinicians have made great strides in
eliminating urosepsis from the renal transplant population. A
regimen of low-dose trimethoprim-sulfamethoxazole (one sin-
gle-strength tablet at bedtime) or ciprofloxacin (250 mg at
bedtime) for 6 to 12 months after transplantation has virtually
eliminated urosepsis from this patient group. A trimethoprim-
sulfamethoxazole regimen has the added benefit of providing
effective prophylaxis against Pneumocystis carinli, Nocardia
asteroides, and Listeria monocytogenes as well [73—75].
Conventional bacterial infection of two general types, both of
which stem from the gastrointestinal tract, can affect the
transplant recipient. Acute bacterial gastroenteritis due to non-
typhoidal Salmonella species, Campylobacter jejuni, or Liste-
na monocyto genes is common in renal transplant patients who
don't receive anti-UT! prophylaxis. In the case of salmonella
infection, transient bacteremia seeding the cardiovascular sys-
tem is of major concern, and early antimicrobial therapy is
clearly indicated. Once seeding has occurred, relapsing blood
stream infection can require extended courses of antibiotics.
The second form of bacterial GI infection that affects the renal
transplant patient is diverticulitis, which is accompanied by a
high rate of perforation. Although patients receiving immuno-
suppressive drugs (for example, corticosteroids) can perforate
any site of weakness in the GI tract (peptic ulcers, diverticula,
etc.), the most vulnerable site for perforation is the sigmoid
colon, Surgical resection under coverage of broad-spectrum
antibiotics usually is required in these patients [1].
Mycobacterium tuberculosis infection occurs in renal trans-
plant patients at a rate more than a 100 times that of the general
population [11. The clinical presentations, more varied than in
the general population, include miliary disease in addition to
cavitary pulmonary disease and gastrointestinal disease as well
as cutaneous disease. This patient population also is subject to
an unusally high rate of bone and joint involvement [1]. On the
other hand, the great majority of individuals with positive
tuberculin tests before transplantation, and no other risk factors
for active tuberculosis, do not develop active disease. The
additional risk factors for active tuberculosis include: Asian,
African, or Native American heritage; the presence of other
immunosuppressing conditions such as protein malnutrition; a
history of active tuberculosis, particularly if it had been inade-
quately treated; and the presence of significant abnormalities on
chest radiograph. Because of the difficulties in utilizing drugs
such as isoniazid and rifampin in patients with a high incidence
of hepatic dysfunction, and because of the potential interaction
of these drugs with cyclosporine, we reserve anti-tuberculous
prophylaxis for patients with these additional risk factors for
active disease. Patients with positive tuberculin tests without
risk factors are followed closely, and we obtain chest radio-
graphs every 6 months. We treat patients with active disease for
at least 12 months with a minimum of two bactericidal drugs
(isoniazid, rifampin, or pyrazinamide) [1, 76].
In addition to typical mycobacterial infection, atypical my-
cobacterial bacteria infect renal transplant patients. These
infections can be divided into two general categories: pulmo-
nary, cutaneous, skeletal, or disseminated infection due to M.
kansasii; or cutaneous infection alone, usually after injury to
the skin, caused by mycobacterial species M. maninum, M.
haemophilum, or M. chelonei [1, 76].
The most important cause of opportunistic bacterial infection
in transplant patients is Listenia monocytogenes. Activated
macrophages are critically important in killing these organisms,
which are otherwise capable of persisting intracellularly, so it is
not surprising that transplant patients are particularly suscepti-
ble to this infection. Listeria are gram-positive bacilli whose
portal of entry is the gastrointestinal tract and whose major
impact following blood stream invasion is on the central ner-
vous system. The clinical syndromes observed are bacteremia,
sometimes in the setting of a gastroenteritis syndrome; an acute
or subacute meningitis; meningoencephalitis; and cerebritis
without concomitant meningitis. Any portion of the brain can
be affected, but listeria have a particular predilection for the
brain stem, at times producing a clinical syndrome that mimics
bulbar polio. Treatment of listeria infection always should
include meningeal doses of penicillin or ampicillin, with or
without gentamicin, or trimethoprim-sulfamethoxazole for 14 to
21 days, as CNS seeding is likely [1, 771.
Nocardia asteroides, although often grouped with fungal
infections because of a common pathogenesis and clinical
presentation, occasionally causes opportunistic bacterial infec-
tion in transplant patients. The patient typically presents with
cough, fever, and one or more focal infiltrates abutting the
pleura on chest radiograph. This organism also has a high
propensity for invading pulmonary blood vessels and metasta-
sizing to the skin, central nervous system, or other sites.
Indeed, disseminated disease, particularly of the skin, can lead
to the recognition of disseminated nocardial infection [761.
Fun gal infections
Fungal infection in the renal transplant patient comprises two
general categories: disseminated infection with one of the
geographically restricted systemic mycoses (histoplasmosis,
coccidioidomycosis, or blastomycosis); and opportunistic in-
fection with agents that rarely infect the normal host (Candida
species, Pneumocystis caninhi, Aspergillus species, Cryptococ-
cus neoformans, and the Mucoraceae). A variety of clinical
presentations should prompt one to consider the geographically
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restricted mycoses in transplant patients who have been ex-
posed to the specific geographic areas. These symptoms include
a subacute respiratory illness, with either focal or disseminated
interstitial or miliary infiltrates on chest radiograph; a nonspe-
cific febrile illness; or an illness in which disseminated aspects
of the infection predominate (for example, mucocutaneous
manifestations in histoplasmosis and blastomycosis, or central
nervous system manifestations in coccidioidomycosis). Am-
photericin therapy remains the standard of care for these
entities, although increasing experience with the new azole
antifungal agents, fluconazole and itraconazole, suggests that
they are valuable for completing a course of treatment after
clinical control has been achieved [1].
Candidiasis. Candida species are commonly found on dis-
eased skin, throughout the entire gastrointestinal tract, and in
the vagina. Overgrowth of these mucocutaneous surfaces oc-
curs when increased nutrients are available to support candidal
growth, because of suppression of bacteria by antibacterial
therapy, or because of metabolic factors (diabetes, corticoste-
roid therapy, pregnancy, etc.). Not surprisingly, then, the most
common manifestation of candidal infection in the transplant
patient is mucocutaneous overgrowth, as evidenced by thrush
in the pharynx, candidal esophagitis, vaginitis, intertrigo,
and/or paronychia or onychomycosis. Topical therapy with
nonabsorbable fungal agents such as clotrimazole or nystatin
are usually effective in controlling candidiasis, provided the
underlying condition is corrected. When topical therapy fails,
or concern exists regarding early invasion, fluconazole therapy
is highly effective. It is our practice to prevent mucocutaneous
candidal overgrowth in transplant patients by prescribing oral
nystatin or clotrimazole when antibacterial therapy is em-
ployed, particularly in diabetics [1].
After candidal overgrowth has occurred, the next step in the
pathogenesis of life-threatening infection is penetration beyond
the mucocutaneous barrier. In transplant patients this result
usually has an iatrogenic cause—intravenous lines, bladder
catheters, surgical trauma, etc. An important clinical syndrome
in renal transplant patients is illustrated by the third patient
presented: asymptomatic candiduria was initiated via a bladder
catheter in a diabetic man with poor bladder function, Obstruc-
tive uropathy due to a fungal ball at the ureterovesical junction
resulted, which was accompanied by candidal pyelonephritis
and blood stream invasion. This relatively common sequence of
events has led us to vigorously treat candiduria in transplant
patients, preferably with fluconazole, or with low-dose ampho-
tericin plus flucytosine in patients with fluconazole-resistant
infection [1].
Blood stream invasion significantly increases the likelihood
of disseminated infection with visceral seeding in the allograft.
Whereas normal hosts with transient candidemia develop dis-
seminated infection 1% to 5% of the time, this figure rises to at
least 50% in transplant patients. Every documented episode of
invasive candidal infection in this patient population therefore
demands effective systemic therapy. The clinical manifestations
of disseminated candidal infection in the transplant patient are
diverse, ranging from an acute septic picture to situations in
which the disseminated lesion predominates (for example, skin
lesions, ocular seeding, ostemyelitis, meningitis) [I].
Thus, as the third patient presented exemplifies, candidal
infection, even when initially associated with minimal symp-
toms, should be approached aggressively in transplant patients.
The major advance in the therapy of candidal infection in renal
transplant patients has been the introduction of fluconazole.
This new triazole is very active against C. albicans and C.
tropicalis, the two major species of Candida causing disease in
transplant patients, as well as other less common species. In
contrast, C. krusei and Toru/opsis glabrara should be consid-
ered fluconazole-resistant. Fluconazole can be administered
either orally or intravenously, so effective concentrations of the
drug can reliably be achieved in blood, urine, and cerebrospinal
fluid, even in the presence of achlorrhydria. Fluconazole ap-
pears not to be significantly nephrotoxic by itself, and to be
significantly less hepatotoxic than other drugs of this class.
Because it does affect cyclosporine metabolism somewhat
(although less so than ketoconazole or itraconazole), monitor-
ing of blood cyclosporine levels and renal function are usually
necessary to allow minor adjustments in cyclosporine dose. In
our experience with more than 90 organ transplant recipients
who had invasive candidal or cryptococcal infection, we noted
the following: The drug is well tolerated, even in the presence of
pre-existing renal or hepatic dysfunction. It is quite effective,
although prolonged courses of therapy may be required, as in
the patient presented. It is significantly more "user friendly" in
this clinical situation than is amphotericin-based treatment. Let
me offer one word of caution based both on our experience with
transplant patients and AIDS patients: amphotericin gains
control of both candidal and cryptococcal infection faster than
fluconazole does, although by the end of therapy there appears
to be little, if any, difference in outcome. Therefore, if the
patient is acutely ill and therapy is needed promptly, ampho-
tericin should be administered until the patient stabilizes, at
which time the less toxic fluconazole can be substituted. If the
patient is less acutely ill, our current drug of choice is flucon-
azole for the entire course of therapy [78, 79].
Pneumocystis carinii. The incidence of pneumonia due to this
organism, now classified as a fungus, in renal transplant pa-
tients is approximately 5% to 10%, and I would surmise
probably closer to 10% in the current era of immunosuppres-
sion. As I previously noted, P. carinii is closely linked to the
occurrence of CMV infection and occurs primarily one to six
months after transplantation and also any time in the 5% to 15%
of patients who chronically do not do well. Pneumocystis
pneumonia usually presents subacutely in the transplant pa-
tient. Manifestations include fever, nonproductive cough, ra-
diographic evidence of interstitial pneumonia, and hypoxemia
out of proportion to either physical or radiographic findings.
Two major advances have occurred in recent years regarding
pneumocystis infection in renal transplant patients: (1) The
utility of monoclonal antibody techniques for rapid diagnosis
using induced sputum or bronchoalveolar lavage specimens has
obviated the need for biopsy in most patients. (2) Low-dose
trimethoprim-sulfamethoxazole, often prescribed as urinary
tract infection prophylaxis, provides almost 100% prophylaxis
against pneumocystis. Also, monthly administration of aerosol-
ized pentamidine in patients who can't tolerate the standard
regimen appears to be similarly effective. We must continue to
emphasize prevention of pneumocystis infection, because the
high doses of trimethoprim-sulfamethoxazole and pentamidine
needed to treat full-blown disease have a high rate of adverse
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interaction with cyclosporine and can produce oliguric renal
failure [1, 75].
Aspergillus species. Invasive pulmonary, and occasionally
sinus, aspergillosis is a life-threatening opportunistic infection
that occurs in renal transplant patients after either an unusually
intense exposure or in the presence of excessive immunosup-
pression, Aspergillus infection in recent years has arisen from
exposures resulting from construction within the hospital envi-
ronment. Aspergillus fumigarus accounts for the great majority
of these infections, with A. flavus causing most of the remain-
der. The usual clinical presentations of aspergillus infection are
fever alone, fever plus nonproductive cough or chest discom-
fort, or fever plus evidence of disseminated infection, primarily
to the skin or brain. The pathology of invasive pulmonary
aspergillosis consists of a necrotizing bronchopneumonia with
early fungal invasion of blood vessels. Thus, the important
clinical sequelae of blood vessel invasion, thrombosis with
tissue infarction, hemorrhage, and metastasis are an integral
part of the clinical syndrome of invasive aspergillosis in renal
transplant recipients. Amphotericin remains the cornerstone of
therapy for this disease, although itraconazole is sometimes
useful in completing courses of treatment after significant
amphotericin toxicity has occurred [1].
Cryptococcus neoformans. The portal of entry for C. neofor-
mans is the lung. A flu-like syndrome or an isolated pulmonary
nodule can be the clinical findings that lead to a diagnosis of
cryptococcal infection. Pulmonary infection can be followed by
dissemination through the blood stream. Also, this organism
exhibits a particular tropism for the central nervous system. C.
neoformans, the single most common cause of central nervous
system infection in the renal transplant patient, occurs almost
exclusively in the late post-transplant period (more than 6
months after the initiation of immunosuppression). The classic
cause of subacute to chronic meningitis in this patient popula-
tion, it often presents after several weeks of waxing and waning
headaches and fever. Approximately one-third of patients also
note cough related to simultaneous pulmonary infection. The
other major sites of dissemination include the skin and urinary
tract. Diagnosis of cryptococcal infection has been greatly
facilitated by the availability of cryptococcal antigen testing of
blood and cerebrospinal fluid. But patients with isolated pulmo-
nary disease due to C. neoformans can have negative test
results, and a biopsy often is necessary for diagnosis. Because
of toxicity issues, our current preference for therapy of cryp-
tococcosis in all but the most acutely ill patients is fiuconazole.
We have successfully used this agent to treat 12 renal transplant
patients who had cryptococcosis. Amphotericin with or without
flucytosine is available for critically ill patients or those in
whom fluconazole therapy fails. Even prolonged courses of
fluconazole (more than 6 months) given orally on an outpatient
basis are well tolerated in this patient population [1, 77—79].
Mucoraceae. Mucormycosis is an uncommon cause of fungal
infection in the renal transplant patient that occasionally causes
rhinocerebral disease or hemorrhagic pneumonia. Two points
bear emphasis. Any prolonged acidosis, not just diabetic keto-
acidosis, as well as iron-mobilizing therapy with deferoxamine,
predisposes to mucormycosis. Therapy is primarily aggressive
surgery, with high-dose amphotericin administered only to treat
remaining micrOscopic foci [1].
General principles of antimicrobial therapy
Transplant recipients are very vulnerable to untoward drug
interactions with cyclosporine. Antimicrobial agents as a class
probably have the highest rate of such drug interactions. These
interactions are either pharmacokinetic or idiosyncratic. The
key step in the metabolism of cyclosporine occurs via the
hepatic cytochrome p450 enzyme system. Drugs that up-regu-
late this system (rifampin and possibly isoniazid) cause in-
creased cyclosporine breakdown and lead to inadequate immu-
nosuppression with its associated risk of serious graft rejection.
In contrast, other antimicrobial agents down-regulate this en-
zyme system and raise blood levels of cyclosporine (erythro-
mycin; probably the newer macrolides, azithromycin and cia-
rithromycin; ketoconazole; itraconazole; and, to a lesser
extent, fluconazole) [1, 2]. Down-regulation can then be respon-
sible for cyclosporine nephrotoxicity or overimmunosuppres-
sion and infection. Fortunately, if the clinician is aware of these
possibilities, appropriate cyclosporine dose adjustments can be
made by following serial blood levels of this drug when one of
these antimicrobial agents is used [1, 2].
Far more problematic, and probably far more common, are
the idiosyncratic nephrotoxic reactions that occur when one of
a growing list of antimicrobial agents is administered to a
transplant patient who is receiving cyclosporine. The most
common culprits in this regard are amphotericin, aminoglyco-
sides, vancomycin, "pneumocystis doses" of trimethoprim-
sulfamethoxazole, pentamidine, and itraconazole. Let me de-
scribe one of our own clinical experiences. A renal transplant
patient with normal renal function developed oliguric renal
failure following a single 10 mg dose of amphotericin; following
recovery, a second challenge had an identical effect. We have
had similar experiences with single therapeutic doses of gen-
tamicin and intravenous trimethoprim-sulfamethoxazole. These
and other idiosyncratic reactions have helped define our general
approach to antimicrobial therapy in the cyclosporine recipient.
We rely on extended-spectrum beta-lactam drugs, quinolones,
and fiuconazole. (Even with quinolones, higher doses can pose
a concern; we have observed toxicity with doses of ciproflox-
acm greater than 800 mg/day in transplant patients with normal
renal function.) In addition, our general rule remains that, when
unexplained deterioration in renal function occurs in transplant
patients, possible antimicrobial interactions with cyclosporine
must be considered [1, 2].
In essence, antimicrobial drugs can be utilized in the renal
transplant patient in 3 different modes: a theraneutic mode, in
which antimicrobial agents are administered to treat established
disease; a DroDhvlactic mode, in which nontoxic antimicrobial
agents are administered to all individuals to prevent an infection
that is both common enough and important enough to merit
such an approach; and a pre-emntive mode, in which antimi-
crobial agents are administered to a subgroup of patients prior
to the appearance of clinical disease. This last mode is predi-
cated on the use of a laboratory marker or patient chaEacteristic
that identifies the subgroup of individuals with the highest risk
of serious disease at a time when antimicrobial intervention
would be maximally effective in aborting the disease process [2,
80].
Because of the impact of infection on transplant recipients,
and because of the potential for interactions with cyclosporine
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if full-dose therapeutic courses of antimicrobial agents are
required, we place an increasing emphasis on the preventive
strategies—the prophylactic and pre-emptive. Perhaps the best
example of an effective prophylactic strategy is low-dose tn-
methoprim-sulfamethoxazole, which effectively eliminates
urosepsis as well as Pneumocystis carinii, nocardial, and liste-
n infections. Less successful have been standard prophylactic
programs for CMV and EBV infection. Here, the ability to add
pre-emptive therapy with a potent antiviral agent at times of
intensive immunosuppressive therapy or at a pre-clinical stage
of infection appears to add the flexibility needed to optimize
patient care. The goal remains devising a therapeutic prescrip-
tion that permits the safe deployment of optimal immunosup-
pressive therapy. Significant strides have been made in this
regard.
Questions and answers
DR. DAVID SNYDMAN (Director, Clinical Microbiology, New
England Medical Center, Boston, Massachusetts): I'd like to
make a couple of comments and raise one question. The one
issue I might take exception with is that even in the 1970s and
1980s, CMV was a problem. Even with cyclosporine, azathio-
prine, and prednisone immunosuppression, people developed
severe CMV disease.
DR. RuBIN: Dr. Snydman's point is well taken. However, it
is fair to say that in the azathioprine plus prednisone era of
immunosuppression, the highest incidence of CMV disease was
in patients receiving polyclonal antilymphocyte antibody ther-
apy. In the European and Canadian trials, in which cyclospo-
rine and prednisone were the only immunosuppressant drugs
used, the incidence of CMV disease was very low.
DR. SNYDMAN: Not only is the immunosuppression critically
important, but the serologic profiles and differences in risk of
primary infection are sufficiently disparate that in any analysis
of these studies, the serologic characteristics need to be care-
fully spelled out. Studies that include just cyclosporine or
prednisone might or might not have lots of "negative-negative"
matches, in which the risk of CMV was relatively low. We
might have been lulled into a false sense of security. Clearly the
animal model illustrates the point that there is a difference in
immunosuppression.
DR. RUBIN: Again, your point is very well taken: we want our
patients to be characterized. The two major factors in trans-
plant recipients that modulate the effects of CMV infection are
(1) donor and recipient experience with the virus and (2) the
degree of immunosuppression.
DR. SNYDMAN: The first patient presented here was a living-
related recipient, and the second patient was seronegative for
EBV; I assume the donor was seropositive for EBV. Would you
comment on the issue of living-related transplants and CMV? It
has been argued that you don't need to provide CMV prophy-
laxis in a living-related CM V-positive donor to a CM V-negative
recipient [811. We've seen cases like this with or without
immunoglobulin or other kinds of prophylaxis. I'm very con-
cerned about that statement.
DR. RUBIN: I would agree with you entirely about that.
There's no question that recipients of kidneys from living-
related donors can get severe primary CMV. There's a bit of a
circular argument, however. Since these individuals have less
rejection in general, they get lesser amounts of immunosuppres-
sion so their need for OKT3/ATG or ALS is less. That's as
important as whether they are recipients of living related or
cadaveric allografts.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): At the beginning
of your talk, you reviewed the metabolic factors that might
contribute to net immunosuppression. Although I believe that a
given patient can be sicker than another and thus more immu-
nosuppressed, I have difficulty quantitating that difference. You
gave one example, that is, measuring serum albumin. Is there
anything else that one can use to help quantitatively define
these so-called metabolic factors?
DR. RUBIN: Clinicians generally believe that metabolic ab-
normalities contribute to the net state of immunosuppression.
You can demonstrate in vitro that leukocytes from uremics or
those with hyperglycemia have all kinds of functional defects of
white cell function. The correlation of these results with chem-
ical events has been incomplete to say the least. A recent study
by Ruiz et al, in which splenic dysfunction demonstrated in vivo
was correlated with the subsequent risk of infection [821, is a
powerful example of the way to link metabolic abnormalities to
the risk of infection.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center): You mentioned that the notion
of CMV glomerulopathy is not fully accepted but that you are a
believer. Can you summarize the evidence in support of its
existence?
DR. RUBIN: The glomerular lesion was first recognized as an
unusual biopsy result in a renal transplant patient with CMV
infection and allograft dysfunction. This prompted us to do a
study in which our renal pathologists read all renal biopsies
performed on transplant patients with allograft dysfunction
without knowledge of the prospective virologic monitoring that
was being carried out. Two general pathologic patterns were
found: the glomerular lesion, in patients with CMV viremia; and
tubulo-interstitial inflammation characteristic of classical rejec-
tion, in patients without CMV infection. Subsequent studies
have shown that the glomerular lesion occurs in patients with
"viral patterns" of T-cell subsets, that is, "the reversed CD4/
CD8 ratio." In addition, characterization of the lymphocytes in
the renal biopsy specimens revealed this same "viral pattern"
in the glomerulopathic lesions, a predominance of CD8 cells,
which is the reverse of that seen in biopsies from rejected
tissue. We also have found that the glomerulopathy is only
found in renal allografts. We have not found it in renal biopsy
specimens from patients with heart, liver, or bone marrow
transplants.
DR. ANDREW KING (Division of Nephrology, New England
Medical Center): You stress the importance of preventing
infections. What specific guidelines do you give your patients
regarding infectious exposure in the community or occupational
exposure?
DR. RuBIN: We try to educate patients to avoid heavy
construction sites, travel to third-world countries, or individu-
als who have respiratory infections. A key issue is prevention of
influenza. The possible use of amantadine in this patient popu-
lation should be carefully studied, as the efficacy of conven-
tional influenza vaccination is questionable in this population.
DR. AJAY SINGH (Division of Nephrology, New England
Medical Center): I would like to turn to your hypothesis that the
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atypical glomerulopathy seen with CMV might be due to the
action of cytotoxic T-cells. As you know, OKT3 is directed
against CD3, a pan-T-cell marker, and thus it would be ex-
pected to deplete both CD4+ and CD8+ T-cells [83]. In point of
fact, OKT3 markedly blocks cytotoxic T-cell-mediated cell
lysis [84]. Therefore, if your hypothesis were correct, one
would not expect to see much CMV glomerulopathy in patients
treated with OKT3. Have you observed this in a clinical
setting?
DR. RuBIN: We don't have any information on this point, as
the incidence of the glomerulopathy has markedly decreased
since cyclosporine came along.
DR. SINGH: In view of the similarity in action of both FK506
and cyclosporine in the laboratory, that is, both bind the same
intracellular protein and inhibit IL-2, one would expect that
they both would have similar patterns of primary post-trans-
plant infection. Have you any information on this?
DR. RuBIN: FK506, at least in the mouse, is just like
cyclosporine, so I suspect that you are right.
DR. KLEMENS MYER (Division of Nephrology, New England
Medical Center): Let me follow up on Dr. King's question
about relatively healthy transplant patients. What advice do
you give to patients contemplating dental work?
DR. RuBIN: We generally utilize the same approach to dental
work in transplant patients as that recommended by the Amer-
ical Heart Association for endocarditis prophylaxis.
DR. MYER: In effect, you're treating the presence of a
transplant as a lesion.
DR. RuBIN: That is correct, although I would emphasize that
we do not have data supporting this. It just appears to be a
reasonable course of action.
DR. HARRINGTON: You briefly mentioned problems with the
use of interferon. Can one block its adverse effects and keep its
good ones?
DR. RUBIN: In our studies with alpha interferon prophylaxis,
we utilized the natural, leukocyte-derived product and ob-
served no adverse effects on the allograft, mild to moderate
benefits in terms of antiviral effects, and moderately severe
systemic symptoms of fever and malaise as well as leukopenia.
Trials with recombinant alpha interferon in Europe have had to
be terminated because of a high rate of graft loss that presum-
ably was related to the interferon. At present, my view is that
interferon in transplant patients has only moderate antiviral
effects and significant toxicity, and therefore I would be very
cautious about using it.
DR. SNYDMAN: One of our patients recently died of tubercu-
losis. Would you comment on TB screening and prophylaxis in
your program?
DR. RUBIN: What race was the patient, and what were the
results of the chest x-ray?
DR. MYER: Thepatient was a diabetic woman in her 60s, who
had received an emergency kidney transplant 8 months earlier
after failure of vascular and peritoneal access. Rejection had
been treated with methyiprednisolone and OKT3.
DR. SNYDMAN: What about her background risk for TB?
What do you know about that?
DR. MYER: She had some inactive pulmonary nodules.
DR. RuBIN: Was she Caucasoid?
DR. MYER: Yes.
DR. RuBIN: The management of previous tuberculosis in a
transplant patient is both difficult and controversial. On the one
hand, reactivation of TB, with the risk of systemic dissemina-
tion, is more common in transplant patients than in the general
population. On the other hand, isoniazid prophylaxis is ren-
dered difficult by the 10% incidence of liver dysfunction present
in transplant recipients. Our approach has been to initiate
isoniazid prophylaxis in patients with positive PPDs and an
additional risk factor. The risk factors we consider important
include the following: history of previously active disease, a
clearly abnormal chest x-ray, non-Caucasoid race, protein-
calorie malnutrition, and the presence of some other immuno-
suppressing illness. We have now followed a group of 70
patients with positive PPDs and no risk factors, who did not
receive isoniazid, for more than 7 years post transplant without
seeing a single case of TB. However, when one embarks on this
course, one must be prepared to be very careful in terms of
followup.
DR. MADIAS: You mentioned the long-term risks of cirrhosis
and hepatocellular carcinoma as late sequelae of hepatitis in
transplant recipients. Are any data available on the magnitude
of these risks?
DR. RuBIN: In summary, if transplant patients live long
enough with hepatitis and immunosuppression, they will die of
either cirrhosis or hepatocellular carcinoma.
DR. HARRINGTON: Do any known genetic factors predispose
to B-cell transformation?
DR. RuBIN: I am unaware of any.
Reprint requests to Dr. R. Rubin, Infectious Disease Unit, Massa-
chusetts General Hospital, Boston, Massachusetts 02114, USA
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